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Tumour necrosis factor (TNF)-based isolated limb perfusion (ILP) is an approved and registered treatment for sarcomas confined to
the limbs in Europe since 1998, with limb salvage indexes of 76%. TNF improves drug distribution in solid tumours and secondarily
destroys the tumour-associated vasculature (TAV). Here we explore the synergistic antitumour effect of another vasoactive agent,
histamine (Hi), in doxorubicin (DXR)-based ILP and evaluate its antivascular effects on TAV. We used our well-established rat ILP
model for in vivo studies looking at tumour response, drug distribution and effects on tumour vessels. In vitro studies explored drug
interactions at cellular level on tumour cells (BN-175) and Human umbilical vein endothelial cells (HUVEC). There was a 17% partial
response and a 50% arrest in tumour growth when Hi was combined to DXR, without important side effects, against 100%
progressive disease with DXR alone and 29% arrest in tumour growth for Hi alone. Histology documented an increased DXR leakage
in tumour tissue combined to a destruction of the TAV, when Hi was added to the ILP. In vitro no synergy between the drugs was
observed. In conclusion, Hi is a vasoactive drug, targeting primarily the TAV and synergises with different chemotherapeutic agents.
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Tumour necrosis factor (TNF)-based isolated limb perfusion (ILP)
is an approved and registered treatment for sarcomas confined to
the limb in Europe since 1998 and is currently carried out in
approximately 30 cancer centres with referral programmes for
limb salvage around the continent (Eggermont et al, 1996a).
Isolated limb perfusion with TNF and melphalan also yields
excellent antitumour effects against melanoma (Lienard et al,
1992) and various other tumours in the clinical setting (Bickels
et al, 1999; Olieman et al, 1999; Eggermont et al, 2003). The
mechanism of action is based on the vasoactive effects of TNF,
leading to a significant enhancement of tumour-selective melpha-
lan uptake (de Wilt et al, 2000) and secondarily to a complete
destruction of tumour vasculature (Eggermont et al, 1996b).
An important drawback of the use of TNF is its highly toxic
nature mandating strict monitoring of leakage to the systemic
compartment during ILP. Moreover, this toxic profile of TNF
limits expansion of its use to less controllable sites. Therefore,
other possible vasoactive drugs were sought and tested in our
preclinical rat ILP model as potential candidates (Brunstein et al,
2004; Hoving et al, 2005). In this perspective, we showed strong
synergy of histamine (Hi), an inflammatory mediator, when
combined to melphalan in ILP, including a 66% overall response
rate (OR) with 33% complete responses (CR) (Brunstein et al,
2004).
The aim of this study is to evaluate the effects of Hi on TAV
by means of histological studies and also explore whether the
synergistic effect of Hi would also apply to the combination with
doxorubicin (DXR), an important chemotherapeutic drug in solid
tumour treatment (Santoro et al, 1995; O’Byrne and Steward,
1999). Based on the assumption that DXR is the best single agent
for systemic therapy, with activity in more than 20% of the treated
patients, some Italian centres use it in the TNF-based ILP instead
of melphalan, with circa 26% complete histologic necrosis (Rossi
et al, 1999, 2005). Using the experimental ILP model in rats
bearing syngenic soft-tissue sarcomas, the ability of the combined
treatment to improve tumour response is evaluated. The effects of
Hi on endothelial cells and TAV as well as on drug distribution are
evaluated in vivo, taking advantage of the natural fluorescence of
DXR and combining different histological stainings.
MATERIALS AND METHODS
ILP protocol
Male inbred Brown Norway rats were obtained from Harlan-CPB
(Austerlitz, the Netherlands), weighing 250–300g and were fed a
standard laboratory diet ad libitum (Hope Farms Woerden, the
Netherlands).
Small fragments (3mm) of the syngeneic BN-175 sarcoma were
inserted subcutaneously in the right hind leg of the animals as
described previously (de Wilt et al, 1999). Tumour growth was
measured daily with a calipre and the volume was calculated using
the formula 0.4(A
2 B) (where B represents the largest tumour
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sdiameter and A is the diameter perpendicular to it). When tumour
diameter exceeded 25mm rats were killed by cervical dislocation,
under anaesthesia. At the end of the experiment all the rats were
killed by the method specified.
The treatment consisted of the experimental ILP, as described
previously (de Wilt et al, 1999). Briefly, 7–10 days after
implantation, tumours reached a diameter between 12 and
15mm and were amenable to the procedure. Under anaesthesia
(intraperitoneal ketamine and intramuscular hypnomidate), the
inguinal vessels were reached through an incision parallel to the
inguinal ligament, canulated and connected via a roller pump to
an oxygenated reservoir where drugs were added in boluses. A
groin tourniquet occluded collateral vessels, warranting a proper
isolation of the limb.
The 5ml total volume perfusate consisted of: haemaccel alone
(Boehring Pharma, Amsterdam, the Netherlands); haemac-
celþ400mg DXR (80mgml
 1) (Adriablastina
s, Farmitalia Carlo
Erba, Brussels, Belgium); haemaccel þ 1000mg Hi (200mgml
 1)
(kindly provided by Maxim Pharmaceuticals Inc., San Diego, CA,
USA) or haemaccel with 400mg DXR and 1000mg of Hi.
Tumour dimensions were measured every day for volume
calculation. Response was classified as: progressive disease (PD),
increase of more than 25%; no change (NC), volume kept in the
range of  25 to þ25%; partial remission (PR), decrease between
 25 to  99% or complete response (CR), no palpable tumour,
initial volume as compared to volume on day 9.
Limb function was clinically observed as the ability to walk and
stand on the perfused limb after ILP. On a scale from 0 to 2, grade
0 is a severely impaired function where the rat drags its hind limb;
grade 1, a slightly impaired function (cannot use it in a normal
way, but stand on it);and finally, grade 2 is an intact function
(normal walking and standing pattern).
Locoregional toxicity was also evaluated by clinical observation
of limb oedema. Oedema was defined as absent ( ), or present,
and in this case graded in a scale from þ to þþþþ, according
to the extent of increase in volume of the treated limb as compared
to the opposite, not treated limb.
The studies were carried out in accordance with protocols
approved by the Animal Care Committee of the Erasmus
University Rotterdam, the Netherlands.
Histologic evaluation after Hi-based ILP
Two animals for each group were killed by cervical dislocation
directly and 24h after ILP, and tumours and a piece of underlying
muscle were excised, fixed in 4% formaldehyde solution and
embedded in paraffin. The slides were stained with haematoxylin
and eosin and CD-31 by the Pathology Department of the Erasmus
MC. Images were taken on a Leica DM-RXA microscope supplied
with a Sony 3CCD DXC camera.
Perls iron staining – histologic evaluation after Hi-based ILP
Two animals for each group were killed by cervical dislocation 7
days after ILP, and tumours and a piece of adjacent muscle were
excised, fixed in 4% formaldehyde solution and embedded in
paraffin. The slides were stained by Perl’s method, a qualitative
technique based on the release of ferric iron from hemosiderin by
acid treatment, forming ferric chloride. The ferric iron reacts with
potassium ferrocyanide to form ferric ferrocyanide, an insoluble
blue compound known as Prussian blue (Bancroft and Cook,
1984). Images were taken on a Leica DM-RXA microscope supplied
with a Sony 3CCD DXC camera.
DXR distribution and evaluation of vascular function
To gain insight into in vivo intratumoral drug distribution, three
animals for DXR alone and three for Hi þ DXR were submitted
to standard ILP plus the addition of 20ml of the vessel staining
FITC-lectin (Bandeireae simplicifolia, BS-I Isolectin B4, Sigma,
Zwijndrecth, the Netherlands) to the perfusate. Directly after the
procedure, the animals were killed by cervical dislocation, tumours
were excised, snap frozen in liquid nitrogen and stored at  801C.
Thick sections of 25mm were mounted with Mowiol and evaluated
by confocal microscopy with a Zeiss LSM 510 Meta (488nm laser
with 505–505 band pass filter (FITC) and 543nm laser with 560
long-pass filter (DXR)). Nine different fields per animal were
selected and photographed (three fields per slide, in a total of three
slides per animal). Images were further processed, using Image
Tool
s for Windows 2000. First, the colours of the images were
separated, for quantification of vessel density (green) and drug
distribution (red). Next, images were binarised, with a lower
threshold setting based on the negative control, and percentage of
positive pixels was determined. Data were plotted with GraphPad
Prism for Windows 2000.
Immunohistochemistry staining antialbumin
For the evaluation of the presence of albumin extravasation into
the tumour, two rats submitted to each of the following ILP: (1)
sham; (2) DXR; (3) Hi or (4) HiþDXR were included in this study.
Tumours were excised, fixed in 4% formaldehyde solution and
embedded in paraffin right after the ILP.
Sections were deparaffinised, rehydrated and treated with 10mM
sodium citrate buffer, pH 6.0, at 1001C in a microwave oven for
10min. Next, the slides were washed and incubated with rabbit-
anti rat albumin (Nordic Immunological Laboratories, Tilburg,
the Netherlands) at 1:1000 in Phosphate buffered saline (PBS),
overnight at 41C. After washing, antibody binding was detected
using diaminobenzidine substrate-chromogen (Sigma-Aldrich,
Zwijndrecth, the Netherlands) for 5min at room temperature.
Slides were counterstained with Mayer’s haematoxylin, dehydrated
with ethanol, cleared with xylene and finally mounted with
Entellan (Merck, Darmstadt, Germany). Images were taken on a
Leica DM-RXA microscope equipped with a Sony 3CCD DXC
camera.
Martius/scarlet/blue (MSB) for connective tissue and fibrin
Two rats submitted to each of the following ILP: (1) sham, (2)
DXR, (3) Hi or (4) HiþDXR were included in this study. Tumours
and underlining muscle were excised, fixed in 4% formaldehyde
solution and embedded in paraffin right after the ILP. Tumour
slides were first deparaffinised and hydrated before being stained
by MSB method for fibrin. Shortly, slides were placed in Martius
yellow (Sigma) for 2min, rinsed with distilled water; placed in
Crystal scarlet (Ponceau 6R) (Sigma) for 10min; differentiated
with Phosphotungstic acid (Sigma) until only fibrin was red (circa
10min); and placed in Methyl blue (Sigma) until collagen was blue
(also circa 10min). Then, slides were briefly rinsed with 1%
aqueous acetic acid, rapidly dehydrated with ethanol, cleared with
xylene and finally mounted with Entellan (Merck). Images were
taken on a Leica DM-RXA microscope equipped with a Sony 3CCD
DXC camera.
Cytotoxicity assay
Direct interaction between DXR and Hi was evaluated in vitro on
BN-175 tumour cells and endothelial cells.
BN-175 tumour cells (isolated from the spontaneous, rapidly
growing and metastasizing soft-tissue sarcoma) (Kort et al, 1984)
were grown in RPMI-1640 essential medium (Life Technologies,
Breda, the Netherlands) supplemented with 10% foetal calf serum
and 0.1% penicillin–streptomycin (Life Technologies, Breda, the
Netherlands).
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sCells were plated 24h before treatment in 96-well, flat-bottomed,
microtitre plates (Costar, Cambridge, MA, USA) at a concentration
of 10
5 cellsml
 1, final volume of 100ml and allowed to grow as a
monolayer. Next, they were incubated at 371Ci n5 %C O 2 for 48h
in the presence of medium alone or medium plus different
concentrations of DXR and Hi. Histamine ranged from 0 to
200mgml
 1 and DXR from 0 to 5mgml
 1.
Growth of tumour cells was measured using the sulphorhoda-
mine-B (SRB) assay (Skehan et al, 1990). In brief, cells were
washed with PBS, incubated with 10% trichloric acetic acid for 1 h
at a temperature of  41C and washed again. Cells were stained
with SRB for about 15–30min, washed with 1% acetic acid and
allowed to dry. Protein-bound SRB was dissolved in TRIS (10mM,
pH 9.4). Extinction was measured at 540nm and the percentage
of growth inhibition was calculated according to the formula:
percentage of tumour cell growth¼(test well/control well) 100%.
The drug concentration leading to 50% reduction in absorbance, as
compared to control (IC50), was determined from the growth
curve. The experiments were repeated four times.
Human umbilical vein endothelial cells (HUVEC) were prepared
by collagenase treatment of freshly obtained human umbilical
veins and cultured in human endothelial–SFM/RPMI medium
(Life Biotechnologies, Breda, the Netherlands) supplemented with
10% heat-inactivated human serum (Cambrex, Verviers, Belgium),
20% new born calf serum, human EGF, human bFGF and 0.1%
penicillin–streptomycin (Life Technologies, the Netherlands).
Human umbilical vein endothelial cells were plated 24h before
treatment in 96-well plates at 6 10
4cellsml
 1, total volume of
100ml and allowed to grow as a monolayer. Next, they were
cultured for 48h with Hi, in concentrations ranging from 0 to
200mgml
 1 and DXR from 0 to 0.5mgml
 1. The growth and IC50
were determined in the same way as for the tumour cells.
Statistical analysis
Kruskal–Wallis and Mann–Whitney U-tests were used to evaluate
statistical significance of the results. All statistical tests were two-
sided and P-values less than 0.05 were considered as statistically
significant. Calculations were performed on a personal computer
using Prism v3.0 software (GraphPad Software Inc., San Diego, CA,
USA) and SPSS v10.0 for Windows 2000.
RESULTS
Tumour response after ILP
While tumours grew exponentially in all rats submitted to either
control or DXR alone ILP, Hi alone could arrest tumour growth for
4 days in two out of seven animals (29%). As expected, the best
response was seen with the combination of Hi and DXR showing
a partial regression in two animals (33%) and arrest of tumour
growth for approximately 6 days in three animals (50%) (Po0.01
on day 8 for Hi þ DXR as compared to sham; P¼0.027 on day 8
for Hi þ DXR as compared to DXR alone) (Figure 1; Table 1).
As previously seen in Hi þ melphalan ILP, Hi either alone or
combined with DXR did not inflict systemic side effects. As for
regional toxicity, we observed a very mild (þ) oedema in 17% (one
out of six) of the rats treated by HiþDXR and 14% (one out of
seven) of those treated by Hi alone ILP, leading to a temporary
grade 1 toxicity. The oedema compromised the limb as whole,
including both the tumour and the normal tissue and was of the soft
kind oedema. Isolated limb perfusion with DXR alone also caused a
temporary regional toxicity in one (17%) of the treated rats scoring
a grade 1 function with limb oedema lasting for 3–4 days.
Histology
Immediately after ILP with Hi þ DXR vasodilation was observed,
accompanied by tumoral endothelial cell damage and haemor-
rhage. Next to that some oedema in the tumour was observed.
Histamine alone ILP resulted in diffuse oedema, but much less
haemorrhage was seen than with the combination of HiþDXR.
Sham (data not shown) or DXR alone ILP had no effect on
vasodilation or haemorrhage and predominantly intact tumour
cells and few necrotic spots were seen. In accordance to these
findings, CD-31 staining clearly showed the Hi-mediated destruc-
tion of the TAV-associated endothelial cell lining, with a more
striking effect observed in those tumours treated by the combina-
tion of HiþDXR as compared to Hi alone ILP. DXR alone ILP
clearly had no effect on endothelial cell lining (Figure 2).
Perls iron staining – histologic evaluation after Hi-based
ILP
In agreement with HE and CD-31 findings, Perl’s method
documented a haemorrhagic effect linked to Hi administration.
Although DXR-alone-treated tumours had some iron deposits 7
days after ILP, mainly in the tumour tissue, these became more
abundant after Hi alone ILP. After HiþDXR ILP though, those
iron deposits were clearly bigger and much more pronounced. As
expected, iron deposits were mostly observed in the rim of the
tumour and close to the vessels. The pattern was exactly the same
as the one previously observed after Hiþmelphalan ILP (data not
shown). Muscle tissue from Hi-treated tumours (both with and
without DXR) showed few and much smaller foci. Sham ILP had
no iron deposits either in muscle or in tumour tissue. These
findings further support the specific TAV-targeting action of Hi
(Figure 3).
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Figure 1 Tumour response in soft-tissue sarcoma bearing rats after Hi-
based ILP. Tumor-bearing rats were submitted to ILP with sham, DXR, Hi
or DXR þ Hi as described in Materials and Methods. Mean tumour
volumes7s.e.m. are depicted. *Po0.01 on day 8 for HiþDXR as
compared to sham; P¼0.027 on day 8 for HiþDXR as compared to DXR
alone.
Table 1 Response in BN-175 soft tissue sarcoma-bearing rats after
doxorubicin-based ILP in combination with Histamine over a total period of
08 days
Treatment
a CR
b PR (%) NC (%) PD (%)
Sham (n¼5) — — — 100
DXR (n¼6) — — — 100
Histamine (n¼7) — — 29 71
Hi+DXR (n¼6) — 17 50 33
aDoxorubicin (DXR, 400mg) and Histamine (Hi, 1000mg) were added as boluses to
the perfusate (5ml).
bResponses were scored as described in Materials and Methods.
CR¼complete response; PR¼partial response; NC¼no change; PD¼progressive
disease.
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sAlbumin extravasation and tumour endothelial cell matrix
alterations
To get a better insight into the pattern of oedema an
immunohistochemistry antialbumin staining was carried out.
Likewise already observed in the haematoxylin and CD-31
stainings, the vessels looked dilated after Hi treatment either with
or without the combination to DXR. Extravasated albumin was
observed around, and close to the vessels, once more, this
observation was more striking after HiþDXR ILP (Figure 4).
Given the above findings, an additional staining specific for
collagen and fibrin was carried out (MSB). Apart from the already
expected Hi-related vasodilation, a very interesting observation
was the Hi-related disarrangement of the collagen fibres, which
could possibly play a role in improving tumour drug distribution
(Figure 4). Slides from adjacent muscle showed normal anatomic
structures without significant changes (data not shown), further
supporting the TAV-specific effect of the treatment.
Doxorubicin distribution and TAV evaluation by
FITC–lectin ILP
Taking advantage of the natural red fluoresence of DXR, we
evaluated drug distribution within tumour and muscle by confocal
microscopy of thick slides. When ILP was performed with DXR
alone, some extravasation was observed around perfused (lectin-
positive) vessels. Increased extravasation of DXR was seen around
tumour vessels, when Hi was coadministered, while in muscle no
major effects were observed. Moreover, some areas of DXR leakage
could be observed in the tumour, with diffuse or even absent lectin
staining, indicating severe damage to the endothelial lining of the
tumour vasculature. These observations suggest an increased
leakage specifically from the tumour vascular bed when Hi was
added to the ILP (Figure 5). This finding was confirmed by means
of intratumoral drug distribution quantification carried out
through pixels intensity measurement (Po0.001, DXR alone
compared to DXR combined to Hi). The lectin staining also
HE 16
Hi+DXR Hi DXR
HE 40
CD-31 16
CD-31 40
Figure 2 Tumour vascular destructive effect and haemorrhagic necrosis upon Hi-based ILP. Pictures of representative tumour histology (HE) and vascular
destruction (CD31) right after ILP with DXR, Hi or DXR þ Hi are shown. Orange bar on  16 magnification pictures corresponds to 100mm and red bar
on  40 magnification to 50mm.
Sham Hi DXR Hi+DXR
Tumour
Muscle
Figure 3 Staining by Perl’s method shows Histamine-related induction of necrosis at 7 days after ILP, which is absent in muscle. Original magnification
 10. Black bar corresponds to 100mm.
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srevealed large areas devoid of functional vessels, mainly in the
tumour centre, in which no DXR could be delivered during the
ILP.
Direct cytotoxicity of histamine
To evaluate the potential synergistic action between DXR and Hi,
in vitro cytotoxicity assays were carried out on BN-175 tumour
cells and on HUVEC. As shown in Figure 6, both agents were
capable of killing endothelial cells with an IC50 of 200mgml
 1 for
Hi and an IC50 of 0.1mgml
 1 for DXR. While BN-175 tumour cells
were effectively killed by DXR with an IC50 of 0.08mgml
 1, hardly
any effect of Hi was noticed with an IC50 as high as 500mgml
 1.
Combining DXR and Hi in vitro had only an additive effect.
DISCUSSION
In this study, we show, by combining the natural red fluorescence
of DXR with lectin–FITC staining of functional vessels during ILP,
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Figure 5 Effect of Hi-based ILP on intratumoral DXR distribution in
relation to tumour vessel presence. Directly after ILP with DXR and lectin–
FITC (DXRþLec), or Histamine plus DXR and Lec (HiþDXRþLec)
tumours were excised, frozen and 25mm thick slides were cut. Sections
were examined by confocal microscopy. DXR distribution and vessel
density in digital images were measured as described in Materials and
Methods (A). Representative pictures of intratumour DXR distribution
right after ILP with DXR and lectin–FITC (DXRþLec), or histamineþ
DXR and Lec (HiþDXRþLec) are shown (B).
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Figure 6 Evaluation of possible direct effects of Hi and DXR on BN-175
soft-tissue sarcoma cells and HUVEC. BN-175 tumor cells (A) or HUVEC
(B) were exposed to 0–5mgml
 1 DXR with Hi 0–200mgml
 1 for 72h.
Each point represents an average of four readings. Error bars show s.d.
values.
Hi+DXR Sham Hi DXR
Figure 4 Albumin extravasation and tumor endothelial cell matrix alterations. Upper panel shows MSB staining for connective tissue and fibrin with a clear
disarrangement of collagen fibres seen in tumours submitted to Hi-based ILP. Lower panel depicts most representative slides of Immunohistochemistry
staining with antialbumin where albumin appears in brown, surrounding the vessels in the Hi-treated tumor tissues. More striking effects were clearly
observed after HiþDXR ILP. Original magnification  16.
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sthat the vascular disrupting effect of Hi augments intratumoral
delivery of DXR. Based on these observations we hypothesise that
both destruction of the tumour-associated vasculature and better
tumour drug distribution, when Hi was administered, added to the
observed augmented tumour responses. Additional histological
stainings, such as CD-31 and Perl’s method, further demonstrated
Hi-related endothelial lining disruption and tumour haemorrhage,
respectively. It is of note that these effects were more intense in
tumour than in the muscle tissue, in agreement with the previously
reported four-fold increase in melphalan uptake by tumour as
compared to muscle (Brunstein et al, 2004). Indeed, it has
been long established that the susceptibility of endothelial cells
to vasoactive agents vary according to their grade of differentia-
tion. Agents such as TNF and Hi have a stimulatory effect on
slowly proliferating cells from resting vessels found on normal
tissue. On the other hand, fast proliferating endothelium as seen in
placenta, wound tissue and tumours have an inhibitory pattern
of response to vasoactive agents, and are consequently
more vulnerable to haemorrhage (Denekamp, 1984; van de Wiel
et al, 1992).
Histamine and TNF have many similarities concerning
their mechanism of action in tumour response after ILP, including
TAV targeting, with an increased tumour drug uptake
accompanied by selective TAV destruction (Brunstein et al, 2004;
Hoving et al, 2006). Furthermore, both Hi and TNF show
synergistic response with chemotherapeutic drugs and both
require the combination of chemotherapeutics to achieve the
best tumour responses after ILP. Yet, it is of note that while a
TNF-alone ILP resulted in progressive disease in all treated
animals, Hi-alone ILP could arrest tumour growth in the range
of 29–50% of the treated animals (this study and Brunstein et al
(2004)).
Accordingly, in vitro studies disclosed a direct cytotoxic effect of
Hi against tumour cells and endothelial cells (HUVEC), while TNF
required the combination with interferon and peripheral blood
mononuclear cells, for having an effect on endothelial cells in vitro
(Seynhaeve et al, 2006).
Speculating on possible mechanisms of Hi-induced endothelial
damage, it shall be taken into account that the gap formation of
endothelial cells occurs via inositol phosphate second messenger
and increased intracellular calcium concentration (Carson et al,
1989). The recovery process however, is mediated by an increased
intracellular cAMP level and negative feedback inhibition, a
pathway shared by ‘endothelial stabilisers’, such as prostaglandin
(PGI2). Histamine stimulates PGI2 production after very short
time incubation periods of 1–2min (Resink et al, 1987; Wu and
Baldwin, 1992) and also stimulates the production of other
eicosanoids such as HETE, which can affect cell function through
incorporation into membrane lipids and altering the properties of
the membrane (Wang et al, 1990). Previous studies showed that
HETE production reduces the production of PGI2 and leads to the
contraction of the endothelial monolayer, finally compromising
endothelial function and contributing to the atherogenic process
(Revtyak and Campbell, 1992).
Another possible mechanism of Hi-related tumour endothelium
damage could be, similarly to the one described to TNF, an
induced congestion causing haemorrhage and oedema by impaired
blood flow and finally resulting in haemorrhagic infarction.
Supporting this theory are the different stainings documenting
an Hi-related vasodilation and haemorrhage. It is already known
for TNF that platelets and von Willebrand factor play a major role
(Nooijen et al, 1996), yet for Hi this process still requires further
investigation.
Furthermore, in this study we show that the antitumour effect of
Hi in a regional therapy model was not restricted to melphalan but
was also present in combination with DXR, resulting in tumour
regressions or tumour growth arrest in 67% of the rats. Histamine
alone arrested tumour growth in 29% of the animals, while tumour
progression was observed in virtually all rats in sham or DXR
alone groups.
Tumour response rates in this study were not as good as those
previously reported for the combination of Hi plus melphalan. Yet,
DXR alone was also less active than melphalan alone in our ILP
model, with no antitumour effect (100% progressive disease) for
DXR, against 17% partial response and 17% tumour growth arrest
for melphalan (Brunstein et al, 2004). These findings are in
accordance with the literature where melphalan is described as the
drug of choice for ILP in most centres worldwide, with the best
response rates and lower complication indexes (Thompson et al,
1998; de Wilt et al, 1999).
A possible explanation for the reduced efficacy of DXR could
be its cycle dependency, while melphalan does not have this
restriction. Taking into account that during an ILP drugs are
delivered in a higher dosage but only once, apposed systemic
chemotherapy where drugs are given repeatedly, this difference in
activity might play an important role. Furthermore, the relatively
poor penetration of DXR has already been reported as probably
related to a rapid uptake of this drug by the perivascular cells.
DXR binds avidly to the DNA within these cells, thus reducing
the amount available for diffusion to distal cells (Primeau et al,
2005). In the case of increased permeability, due to the
combination with vasoactive agents such as TNF or Hi, DXR
would still not perform as well as an alkylating agent, namely
melphalan. On top of this, according to the work of Takemoto
et al (2003), the alkylating reaction with cellular DNA, resulting
in the formation of DNA crosslinks would be most significantly
enhanced at elevated temperatures, with a reported activation
energy for melphalan of 72.477.9kcal, between 37 and 411C,
which is precisely the range of temperature used in the ILP
setting. These authors provided further evidence that alkylating
agents are the best option for regional treatment and also elegantly
showed that the drug of choice at elevated temperatures, such as
those used during regional treatment, might be different from
the drug of choice at the physiological temperature (Takemoto
et al, 2003).
Specifically in the case of Hi, the batch used in this study
was less active in vitro on both tumour and endothelial cells
as compared to previous results (Brunstein et al, 2004), and
possibly resulted in a partial loss of the direct effect of Hi towards
tumour and endothelial cells in vivo. Strikingly, tumour endo-
thelial lining destruction and haemorrhage remained similar
after Hi-based ILP, quite comparable to previous results. This
observation was well documented by the different histologic
stainings used.
An additional important finding of our study is the Hi-related
disarrangement of the collagen fibres, which we speculate could
play an additional role in improving tumour drug distribution.
Further studies, for a better evaluation and understanding of this
important step, in improving tumour response rates with the use
of vasoactive drugs are underway.
In conclusion, the inflammatory mediator Hi acts as a vasoactive
drug, targeting the tumour-associated vasculature and is capable
of synergising with different chemotherapeutic agents. More
importantly, this occurred without systemic side effects and only
a mild regional toxicity, with a temporary limb oedema,
completely reversible after 3–4 days. These findings support a
potential role of Hi in regional treatment and organ perfusions in
the clinic.
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